Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.
More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS.
AstraZeneca and Daiichi Sankyo's Enhertu will become an option for hundreds more people with breast cancer in England and Wales, thanks to new guidance from NICE that will make it available